Payment overview · 2025
General Payments
$435.63
26 reported records · 15 companies
Healthcare provider profile · identity verified
John Paul Greving, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HANNIBAL, MO · NPI 1043388036
Verified facts
What the public records show
CMS Open Payments records show John Paul Greving, DO received $435.63 in general payments during 2025 across 26 reported records.
Amgen Inc. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Brilinta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 204 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.18 | 20.7% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.56 | 10.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.06 | 9.2% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $32.92 | 7.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.28 | 7.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.88 | 7.1% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.37 | 5.4% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $21.37 | 4.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.82 | 4.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.40 | 4.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.41 | 3.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.40 | 3.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.11 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.66 | 3.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.21 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $435.63 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $90.18 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.07 | 4 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $35.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.82 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 39 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 204 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
39 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
315 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
204 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
260 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1186 | 175 |
| Omeprazole | Omeprazole | 952 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 660 | 93 |
| Potassium Chloride | Potassium Chloride | 654 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 623 | 72 |
| Gabapentin | Gabapentin | 614 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 581 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 568 | 91 |
| Lisinopril | Lisinopril | 490 | 73 |
| Metformin Hcl | Metformin Hcl | 422 | 68 |
| Sertraline Hcl | Sertraline Hcl | 410 | 53 |
| Furosemide | Furosemide | 405 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 358 | 53 |
| Ezetimibe | Ezetimibe | 353 | 53 |
| Donepezil Hcl | Donepezil Hcl | 338 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 315 | 62 |
| Jardiance | Empagliflozin | 315 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 311 | 43 |
| Tramadol Hcl | Tramadol Hcl | 309 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 284 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 282 | 34 |
| Famotidine | Famotidine | 280 | 33 |
| Eliquis | Apixaban | 260 | 33 |
| Carvedilol | Carvedilol | 255 | 38 |
| Linzess | Linaclotide | 255 | 39 |
| Montelukast Sodium | Montelukast Sodium | 224 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 31 |
| Losartan Potassium | Losartan Potassium | 223 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 29 |
| Ozempic | Semaglutide | 204 | 34 |
| Pregabalin | Pregabalin | 197 | 26 |
| Meloxicam | Meloxicam | 196 | 27 |
| Trazodone Hcl | Trazodone Hcl | 188 | 24 |
| Irbesartan | Irbesartan | 181 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 37 |
| Memantine Hcl | Memantine Hcl | 171 | 17 |
| Topiramate | Topiramate | 169 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 48 |
| Lorazepam | Lorazepam | 156 | 30 |
| Levetiracetam | Levetiracetam | 155 | 14 |
| Allopurinol | Allopurinol | 150 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 150 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 145 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 133 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 18 |
| Alprazolam | Alprazolam | 122 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 122 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | 14 |
| Mirtazapine | Mirtazapine | 119 | 16 |
| Alendronate Sodium | Alendronate Sodium | 115 | 16 |
| Prednisone | Prednisone | 113 | 57 |
| Midodrine Hcl | Midodrine Hcl | 112 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 111 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 111 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 15 |
| Baclofen | Baclofen | 101 | 15 |
| Chlorthalidone | Chlorthalidone | 101 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 100 | 15 |
| Celecoxib | Celecoxib | 97 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 29 |
| Glipizide | Glipizide | 97 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 97 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 96 | 65 |
| Myrbetriq | Mirabegron | 92 | suppressed |
| Aripiprazole | Aripiprazole | 87 | suppressed |
| Clonazepam | Clonazepam | 86 | 13 |
| Lovastatin | Lovastatin | 85 | suppressed |
| Sucralfate | Sucralfate | 85 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 79 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 13 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 77 | 11 |
| Metformin Hcl Er | Metformin Hcl | 77 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 72 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 70 | 12 |
| Latanoprost | Latanoprost | 70 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 13 |
| Diazepam | Diazepam | 67 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 15 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | 19 |
| Trulicity | Dulaglutide | 64 | 12 |
| Simvastatin | Simvastatin | 63 | 13 |
| Bumetanide | Bumetanide | 62 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 11 |
| Atenolol | Atenolol | 61 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 61 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 40 |
| Fenofibrate | Fenofibrate | 55 | suppressed |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 33 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 53 | 19 |
| Valsartan | Valsartan | 53 | suppressed |
| Finasteride | Finasteride | 52 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 52 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 51 | 14 |
| Spironolactone | Spironolactone | 51 | 11 |
| Fenofibrate | Fenofibrate,micronized | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 17 |
| Acyclovir | Acyclovir | 48 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 48 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 23 |
| Brilinta | Ticagrelor | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 27 |
| Spiriva Respimat | Tiotropium Bromide | 46 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 22 |
| Loperamide | Loperamide Hcl | 43 | 13 |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 11 |
| Cephalexin | Cephalexin | 41 | 25 |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 39 | 39 |
| Phenobarbital | Phenobarbital | 39 | suppressed |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 37 | suppressed |
| Lactulose | Lactulose | 37 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 25 |
| Nystatin | Nystatin | 36 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Carbamazepine Er | Carbamazepine | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Clotrimazole | Clotrimazole | 32 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 30 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Cyclosporine | Cyclosporine | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Theophylline | Theophylline Anhydrous | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Incruse Ellipta | Umeclidinium Bromide | 29 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 28 | suppressed |
| Scopolamine | Scopolamine | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Levocarnitine | Levocarnitine | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Praluent Pen | Alirocumab | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 21 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 20 | suppressed |
| Nystop | Nystatin | 20 | 12 |
| Qulipta | Atogepant | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 14 |
| Folic Acid | Folic Acid | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Ertapenem | Ertapenem Sodium | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $435.63 · 26 records | Amgen Inc. | AIRSUPRA, AREXVY, CAPLYTA, CAPVAXIVE, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, GVOKE HYPOPEN, KISUNLA, Kerendia, OTEZLA, Ohtuvayre, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, Senza, VYNDAQEL, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error